Journal article
Immunization strategies producing a humoral IgG immune response against devil facial tumor disease in the majority of Tasmanian devils destined for wild release
R Pye, A Patchett, E McLennan, R Thomson, S Carver, S Fox, D Pemberton, A Kreiss, AB Morelli, A Silva, MJ Pearse, LM Corcoran, K Belov, CJ Hogg, GM Woods, A Bruce Lyons
Frontiers in Immunology | FRONTIERS MEDIA SA | Published : 2018
Abstract
Devil facial tumor disease (DFTD) is renowned for its successful evasion of the host immune system. Down regulation of the major histocompatabilty complex class I molecule (MHC-I) on the DFTD cells is a primary mechanism of immune escape. Immunization trials on captive Tasmanian devils have previously demonstrated that an immune response against DFTD can be induced, and that immune-mediated tumor regression can occur. However, these trials were limited by their small sample sizes. Here, we describe the results of two DFTD immunization trials on cohorts of devils prior to their wild release as part of the Tasmanian Government's Wild Devil Recovery project. 95% of the devils developed anti-DFT..
View full abstractGrants
Funding Acknowledgements
This work was supported by the Australian Research Council [LP130100218; LP140100508]; and the University of Tasmania Foundation through funds raised by the Save the Tasmanian Devil Program Appeal and Wildcare Inc. The Wild Devil Recovery Project received funding from the Australian Commonwealth and Tasmanian State Governments.